The federal government and states ramp up responses to the coronavirus pandemic as COVID-19 cases in the U.S. hit a milestone; reaction and analysis on ‘The Five.’

Dr. Stephen Hahn, commissioner of the Food and Drug Administration (FDA) has been working closely with the Trump administration to find medicines effective in fighting the coronavirus.

Hahn in a news conference with Trump on March 19 announced the FDA will make experimental drugs, including anti-malaria ones, available to coronavirus patients.

He said he didn’t want to give “false hope” but was optimistic about the treatments.

Trump announces FDA making anti-malaria drug available to test coronavirus treatment

President Donald Trump, left, listens as Food and Drug Administration Commissioner Dr. Stephen Hahn speaks during a news briefing with the Coronavirus Task Force, at the White House, March 19, 2020, in Washington. (Associated Press)

Hahn was sworn in as commissioner of Food and Drugs in December 2017, replacing Dr. Scott Gottlieb who resigned earlier in the year, and has an extensive background in patient care, academic research and executive leadership, according to the FDA’s website.

Before that, he was the University of Texas MD Anderson Cancer Center’s chief medical executive, where he was responsible for managing the center, which takes care of more than 140,000 patients a year. He was also division head, department chair and professor of Radiation Oncology at the university.

From 2005 to 2014 he was chair of the Radiation Oncology department at the University of Pennsylvania’s Perelman School of Medicine.

He is a physician and scientist and specializes in lung cancer and sarcoma.

Hahn has written more than 220 research articles and has experience in clinical trials and medical product development spanning drugs, biologics, medical devices and diagnostics, according to the website.

When he was at the National Institute of Health’s National Cancer Institute he earned the rank of Commander in the U.S. Public Health Service Commissioned Corps and was a fellow in medical oncology and a resident in radiation oncology.

He graduated from the Lewis Katz School of Medicine at Temple University in Pennsylvania and received a bachelor’s from Rice University in Texas, according to the FDA.

Hahn has said he’s interested in expediting the product-approval process.


“In the new era where science is moving so quickly, the agency should be more efficient, and we should have more agility,” he said during his confirmation, according to Market Watch.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Biden plan seeks to aid black community, address racial disparities in COVID-19

Former Vice President Joe Biden’s campaign released Monday afternoon a broad policy proposal aimed at “rooting out systemic racism from our laws, our policies, our institutions, and our hearts,” and helping African Americans in the U.S.– plans released amid the…

Justice Dept. drops probe of ex-FBI official McCabe, a top Trump target

WASHINGTON (Reuters) – The U.S. Justice Department on Friday dropped its criminal investigation of a top target of President Donald Trump, former No. 2 FBI official Andrew McCabe, at the tail end of a week in which the U.S. law-enforcement…

Kellyanne Conway suggests Hatch Act might not apply to aides like her

Counselor to the president Kellyanne Conway, who has been called to testify before Congress for engaging in prohibited political speech under threat of subpoena, says the White House counsel isn’t clear on whether the Hatch Act applies to presidential aides…

RCMP issues dire warning about its ability to police terrorism, foreign interference and cybercrime

The RCMP is sounding an alarm over what it calls “significant resourcing challenges” as demands on its terrorism-fighting and cybercrime investigators grow — and is warning that if it doesn’t get help soon, it might not be able to properly…